Pan Cancer T

Headquarters and Location

Pan Cancer T is headquartered in Rotterdam, the Netherlands, operating as a biotech spin-out from the prestigious Erasmus MC medical center. The company's strategic location in the Netherlands provides access to world-class research infrastructure and a thriving European biotech ecosystem, enabling close collaboration with leading academic institutions and clinical centers.

Founding and History

Founded in 2020 by Dr. Dora Hammerl, Prof. Reno Debets, and Katrien Reynders Frederix, Pan Cancer T emerged from decades of groundbreaking research at Erasmus MC. The company has successfully raised approximately €21 million to date, including a recent €10 million funding round in 2025 combining €5 million from existing investors and a €5 million government-backed loan. This funding supports the advancement of their lead therapy into first-in-human trials.

Therapy Areas and Focus

Pan Cancer T specializes exclusively in oncology, with a particular focus on hard-to-treat solid cancers where traditional therapies have shown limited efficacy. The company's primary therapeutic focus includes:

• Triple-Negative Breast Cancer (TNBC): Addressing one of the most aggressive breast cancer subtypes
• Solid Tumor Malignancies: Targeting various solid cancers through innovative TCR-T approaches
• Adoptive Cell Therapy: Empowering patients' own immune cells to fight cancer
  The company's mission centers on providing treatment options for patients facing the toughest cancer battles, particularly those with limited therapeutic alternatives.

Technology Platform and Modalities

Pan Cancer T's core technology revolves around next-generation T cell receptor (TCR) T cell therapies, specifically:

• PCT1:CO-STIM Platform: The company's lead cell therapy candidate designed for enhanced anti-tumor activity
• TCR Engineering: Advanced T cell receptor modification techniques to improve tumor recognition
• Adoptive Cell Therapy: Harnessing and enhancing the patient's own immune system
• Solid Tumor Targeting: Specialized approaches to overcome the unique challenges of solid tumor microenvironments
  The company's unique blend of scientific rigor, clinical expertise, and operational excellence enables the development of innovative TCR-T cell therapies that offer hope to patients with limited treatment options.

Key Personnel

• Dr. Rachel Abbott: Chief Executive Officer, bringing extensive leadership experience in biotechnology
• Dr. Dora Hammerl: VP R&D and Co-Founder, leading research and development initiatives
• Dr. Tom Holdich: Chief Medical Officer, overseeing clinical development and medical strategy
• Dr. Reinout Hesselink: VP Process Development, managing manufacturing and process optimization
• Lars Ottevanger: VP Finance, handling financial operations and strategic planning
• Prof. Dr. Reno Debets: Co-Founder and Scientific Advisory Board member, Head of Laboratory of Tumor Immunology at Erasmus MC

Strategic Advisors and Board

The company benefits from a distinguished supervisory board including Dr. John Tchelingerian (Chairman), Prof. Dr. Chris H. Bangma, Dr. Michel Briejer, Dharminder Chahal, and Helen Tayton-Martin. The Scientific Advisory Board features renowned experts including Prof. Dr. Chiara Bonini, Dr. David Gilham, Dr. Neil C. Sheppard, Prof. Dr. Hans J Stauss, and Prof. Dr. Henk M.W. Verheul.

Investor Base

Pan Cancer T is supported by leading investors including Index Ventures, Esco Ventures, Avalon Ventures, and C&O Pharma, demonstrating strong confidence in the company's innovative approach and potential for clinical success.

FAQ Section

What is Pan Cancer T's core science and biotech platform?
Pan Cancer T's foundation is built on advanced TCR-T cell therapy technology, representing a cutting-edge drug discovery platform. The company's mechanism of action involves engineering patients' T cells to express enhanced T cell receptors that can better recognize and eliminate cancer cells. This therapeutic platform leverages decades of innovation in adoptive cell therapy, specifically designed to overcome the challenges of treating solid tumors where traditional immunotherapies have shown limited success.

What diseases and therapeutic areas does Pan Cancer T focus on?
Pan Cancer T's therapeutic pipeline is laser-focused on oncology, specifically targeting solid cancers with significant unmet medical needs. The company's primary indication is triple-negative breast cancer (TNBC), one of the most aggressive breast cancer subtypes with limited treatment options. The rare disease focus extends to other solid tumor malignancies where conventional therapies have failed, addressing critical gaps in cancer care for patients with the poorest prognoses.

What programs and products are in Pan Cancer T's pipeline?
The company's pipeline overview centers on PCT1:CO-STIM, their lead asset currently advancing toward first-in-human clinical trials. This clinical pipeline represents a next-generation TCR-T cell therapy specifically designed for women with triple-negative breast cancer. The development stage focuses on preclinical optimization and IND-enabling studies, with the goal of initiating Phase I trials to establish safety and preliminary efficacy in this challenging indication.

What is the latest company news and recent events?
Recent company news includes the successful completion of a €10 million funding round in 2025, combining private investment and government-backed financing. Key milestones include the appointment of experienced leadership team members and advancement of PCT1:CO-STIM toward clinical trials. The company has also strengthened its scientific advisory board with renowned experts in T cell therapy and oncology, positioning for accelerated development.

What clinical trial data and results has Pan Cancer T announced?
While Pan Cancer T is preparing for its first-in-human clinical trials, the company has generated compelling preclinical data demonstrating the potential of PCT1:CO-STIM in solid tumor models. The preclinical results show enhanced T cell activation and tumor targeting capabilities. Clinical outcomes data will be generated as the company advances into Phase I studies, with safety data and preliminary efficacy signals expected from the upcoming first-in-human trial.

What are Pan Cancer T's regulatory interactions and upcoming milestones?
Pan Cancer T is actively engaging with regulatory authorities including the EMA and FDA to support IND submissions for PCT1:CO-STIM. The company is preparing regulatory filings to enable first-in-human studies, with upcoming milestones including IND submission, regulatory clearance, and initiation of Phase I clinical trials. The regulatory status reflects the company's commitment to meeting all safety and efficacy requirements for advancing novel cell therapies.

Who comprises Pan Cancer T's leadership team and what is their track record?
Pan Cancer T's leadership team combines deep scientific expertise with proven pharmaceutical industry experience. The executive team includes co-founders with decades of TCR-T cell therapy research, experienced clinical development leaders from major biotech companies, and operational experts with track records in cell therapy manufacturing. The scientific advisory board features world-renowned experts in immunology, oncology, and cell therapy, providing strategic guidance for the company's innovative programs and ensuring scientific excellence throughout development.